UY25321A1 - Combinaciones de inhibidor de ace-inhibidor de mmp - Google Patents

Combinaciones de inhibidor de ace-inhibidor de mmp

Info

Publication number
UY25321A1
UY25321A1 UY25321A UY25321A UY25321A1 UY 25321 A1 UY25321 A1 UY 25321A1 UY 25321 A UY25321 A UY 25321A UY 25321 A UY25321 A UY 25321A UY 25321 A1 UY25321 A1 UY 25321A1
Authority
UY
Uruguay
Prior art keywords
inhibitor
mmp
ace
combinations
inhibitors
Prior art date
Application number
UY25321A
Other languages
English (en)
Inventor
Jr Joseph Thomas Peterson
Milton Lethan Pressler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22083543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY25321(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of UY25321A1 publication Critical patent/UY25321A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Lass combinaciones de inhibidores de ACE e inhibidores de MMP son útiles para retardar y revertir el proceso de la fibrosis, dilatación ventricular e insuficiencia cardíaca en mamíferos.
UY25321A 1997-12-23 1998-12-22 Combinaciones de inhibidor de ace-inhibidor de mmp UY25321A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6859497P 1997-12-23 1997-12-23

Publications (1)

Publication Number Publication Date
UY25321A1 true UY25321A1 (es) 2004-07-30

Family

ID=22083543

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25321A UY25321A1 (es) 1997-12-23 1998-12-22 Combinaciones de inhibidor de ace-inhibidor de mmp

Country Status (24)

Country Link
US (1) US6133304A (es)
EP (1) EP1047450B1 (es)
JP (1) JP2001526245A (es)
KR (1) KR20010033473A (es)
AR (1) AR015504A1 (es)
AT (1) ATE225187T1 (es)
AU (1) AU751701B2 (es)
BR (1) BR9814422A (es)
CA (1) CA2305436A1 (es)
CO (1) CO4970775A1 (es)
DE (1) DE69808518T2 (es)
DK (1) DK1047450T3 (es)
ES (1) ES2184340T3 (es)
HU (1) HUP0100427A3 (es)
IL (1) IL135428A0 (es)
IS (1) IS5446A (es)
NO (1) NO20003256L (es)
NZ (1) NZ503962A (es)
PE (1) PE20000065A1 (es)
PL (1) PL341335A1 (es)
PT (1) PT1047450E (es)
UY (1) UY25321A1 (es)
WO (1) WO1999032150A1 (es)
ZA (1) ZA9811794B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200102524T2 (tr) * 1999-03-03 2002-02-21 The Procter & Gamble Company Dihetero sübstitüe edilmiş metaloproteaz inhibitörleri.
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
CA2436130A1 (en) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
DE10125882B4 (de) * 2001-05-28 2007-03-29 Esparma Gmbh Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
EP1419767A4 (en) * 2001-08-20 2005-03-16 Ono Pharmaceutical Co MEDICINE FOR TREATMENT OF HEART FAILURE
US7071211B2 (en) * 2002-09-27 2006-07-04 Bausch & Lomb Inc. Small organic molecules that increase the activity of gelatinase a in ocular cells
US7364719B2 (en) * 2002-10-04 2008-04-29 The United States Of America As Represented By The Department Of Health And Human Services Vasoregulating compounds and methods of their use
EP1575511A4 (en) * 2002-11-07 2006-06-28 Us Gov Health & Human Serv NEW TARGET FOR ANGIOGENESIS AND ANTI-ANGIOGENESIS THERAPY
CA2511521C (en) 2002-12-30 2012-02-07 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2005014825A2 (en) * 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
WO2005048985A2 (en) * 2003-11-14 2005-06-02 Baxter International Inc. Alpha 1-antitrypsin compositions and treatment methods using such compositions
WO2005086915A2 (en) * 2004-03-09 2005-09-22 Arriva Pharmaceuticals, Inc. Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor
US20080269282A1 (en) * 2004-08-02 2008-10-30 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
CN100367956C (zh) * 2006-08-29 2008-02-13 陈俊云 用于治疗高血压的药物
WO2009155611A1 (en) * 2008-06-20 2009-12-23 Kinemed, Inc. Compositions for the treatment of fibrotic diseases or conditions
US20110230428A1 (en) * 2008-07-22 2011-09-22 John Wityak Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
US20110082114A1 (en) * 2009-10-01 2011-04-07 Symphony Evolution, Inc. Methods of Treating Aneurysmal Dilatation, Blood Vessel Wall Weakness and Specifically Abdominal Aortic and Thoracic Aneurysm Using Matrix Metalloprotease-2 Inhibitors
EA027451B1 (ru) 2011-08-30 2017-07-31 Схди Фаундейшн, Инк. Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и их применение
BR112014004845A2 (pt) 2011-08-30 2017-04-04 Chdi Foundation Inc pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
CA2916497C (en) 2013-06-26 2022-07-12 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
US10258621B2 (en) 2014-07-17 2019-04-16 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0729938B2 (ja) * 1990-05-11 1995-04-05 フアイザー・インコーポレイテツド 相乗的治療用組成物及び方法
ATE243529T1 (de) * 1995-02-10 2003-07-15 Searle & Co Kombination von ace-hemmern mit aldosteronantagonisten zur behandlung der ventrikulären hypertrophie
EE03965B1 (et) * 1996-05-17 2003-02-17 Warner-Lambert Company Maatriksi metalloproteinaasi bifenüülsulfoonamiidinhibiitorid
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors

Also Published As

Publication number Publication date
DE69808518T2 (de) 2003-06-26
PE20000065A1 (es) 2000-02-11
NO20003256D0 (no) 2000-06-22
DE69808518D1 (de) 2002-11-07
US6133304A (en) 2000-10-17
DK1047450T3 (da) 2003-01-27
CA2305436A1 (en) 1999-07-01
IS5446A (is) 2000-04-14
AU751701B2 (en) 2002-08-22
EP1047450B1 (en) 2002-10-02
PT1047450E (pt) 2003-02-28
KR20010033473A (ko) 2001-04-25
ES2184340T3 (es) 2003-04-01
PL341335A1 (en) 2001-04-09
ATE225187T1 (de) 2002-10-15
EP1047450A1 (en) 2000-11-02
NO20003256L (no) 2000-06-22
WO1999032150A1 (en) 1999-07-01
AR015504A1 (es) 2001-05-02
HUP0100427A2 (hu) 2001-06-28
BR9814422A (pt) 2000-10-10
HUP0100427A3 (en) 2002-11-28
CO4970775A1 (es) 2000-11-07
IL135428A0 (en) 2001-05-20
JP2001526245A (ja) 2001-12-18
NZ503962A (en) 2002-03-28
ZA9811794B (en) 1999-06-29
AU1522099A (en) 1999-07-12

Similar Documents

Publication Publication Date Title
UY25321A1 (es) Combinaciones de inhibidor de ace-inhibidor de mmp
BR9714385A (pt) Método para tratamento e prevenção de deficiência cardìaca e dilatação ventricular
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
TR200103216T2 (tr) Pirimidinon bileşimleri
ES2062812T3 (es) Composicion detergente enzimatica y metodo para estabilizar enzimas.
NO963860L (no) Isoprenyl-transferase-inhibitorer
NO20005928L (no) Bicykliske pyrimidiner og bicykliske 3,4-dihydropyrimidiner som inhibitorer av cellulær proliferasjon
NO20001583D0 (no) Stimulering av hematopoetiske celler in vitro
MY135732A (en) 5,6-trimethylenepyrimidin - 4 - one compounds
AU4424896A (en) Aromatic heterocyclic derivatives as enzyme inhibitors
BR0011130A (pt) Inibidores de metaloproteases
TR200000374T2 (tr) Akut akciğer harabiyeti ve fibrozitinin alfavbeta6 antagonistleriyle tedavisi.
DK0944590T3 (da) Aminoguanidiner og alkoxyguanidiner som proteaseinhibitorer
DK0885881T3 (da) Sulfonylalkanoylaminohydroxyethylaminosulfaminsyrer, der er anvendelige som retrovirale proteaseinhibitorer
ATE277943T1 (de) Trypsininhibitoren
NO993670L (no) Quinoksalin i trippelkombinasjon med proteaseinhibitorer og reverse transkriptaseinhibitorer som medikamenter for behandling av AIDS
ES2184341T3 (es) Un metodo para la prevencion y el tratamiento de la disfuncion del miocardio.
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
ES2168384T3 (es) Derivados de 2-amino-1,2,3,4-tetrahidronaftaleno activos para el sistema cardiovascular.
IT1317295B1 (it) Procedimento per la creazione di sonorizzazioni e basi musicali,particolarmente per scopo ricreativo in ambienti quali discoteche e
ECSP982806A (es) Combinaciones de inhibidor de ace- inhibidor de mmp
ATE362768T1 (de) Prb2/p130 peptidinhibitoren der cdk2 kinaseaktivität
BR0017074A (pt) Combinações de inibidor de ace-antagonista de vasopressina
GR3023044T3 (en) Succinoylamino hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors.
NO970350L (no) Forbindelser anvendelige som anti-formeringsmidler og GARFT-inhibitorer

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20081222